UD
Therapeutic Areas
NeuroDerm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ND0612 | Parkinson's disease motor fluctuations | Phase 3 |
Leadership Team at NeuroDerm
KI
Kengo Isshiki MSc
CEO
TY
Tami Yardeni MA
EVP Clinical Development
KB
Karin Baer BSc
VP Quality
LS
Lilach Shmueli-Dayan MBA
VP Finance
OE
Ofer Ekbali MBA
VP Operations & Interim VP Pharmaceutical Development
ZM
Ziva Mesika BSc
VP Regulatory Affairs
TT
Toshifumi Tada MBA
Board Chair
KT
Kenji Taguchi PhD
Board Member